Medical devices, healthcare technology and the business of care
PMA approval · P910073

ENDOTAK LEAD SYSTEM

Boston Scientific · Decision date Aug 26, 1993

MEDTECHLEDGER EXPLANATIONP910073

What did the FDA approve?

FDA approved the 0060 Series ENDOTAK Lead System on August 26, 1993. The system includes ENDOTAK C Lead Models 0060, 0062, and 0064; Lead Stylet Models 6824 and 6825; ENDOTAK SQ Patch Lead Model 0063; a commercially available AICD Y Connector Model 6836; and Model 0056 Bipolar Positive Fixation Lead and Adapter. It is a transvenous defibrillation leads system used with commercially available AICD Models 15050, 1555, and 1600.

The statement describes the system as intended for treating ventricular tachyarrhythmias in patients at high risk of sudden cardiac death, defined by prior cardiac arrest or inducible sustained hypotensive VT or VF despite conventional antiarrhythmic drug therapy. The statement notes the system does not require a thoracotomy, but physicians should weigh that against possible additional EP testing or thoracotomy if the leads prove ineffective. The SQ Patch Lead is intended only for chronic subcutaneous or submuscular implantation with an ENDOTAK C Lead, not epicardial or pericardial placement.

FDA approval order statement

Approval for the 0060 Series ENDOTAK Lead System. The ENDOTAK Lead System (hereafter referred to as the ENDOTAK Lead System) consists of the following: the ENDOTAK C Lead Models 0060, 0062, 0064; Lead Stylet Models 6824 and 6825; ENDOTAK SQ Patch Lead Model 0063; commercially available AICD Y Connector Model 6836; and Model 0056 Bipolar Positive Fixation Lead and Adapter. The ENDOTAK Lead System is used with commercially available AICD Models 15050, 1555, and 1600. The ENDOTAK Lead System is a transvenous defibrillation leads system and is intended for the treatment of ventricular tacharrhythmias in patients who are at high risk of sudden cardiac death. Such patients are defined as those who have experienced one or more of the following: (1) survived at least one episode of cardiac arrest presumable due to hemodynamically unstable ventricular tachyarrhythmias unassociated with acute myocardial infarction; or (2) recurrent ventricular tachyarrhythmias in the absence of such previous arrest and are inducible into sustained hypotensive ventricular tachycardia (VT) or ventricular fibrillation (VF) despite conventional antiarrhythmic drug therapy.A major consideration in choosing the ENDOTAK Lead System is that it does not require a thoracotomy. The physician should weigh its advantages against the patients ability to withstand additional electrophysiological (EP) testing (arrhythmia induction and conversion testing), and a possible thoracotomy, should the lead system prove ineffective.Various factors such as cardiomegaly or drug therapy may necessitate repositioning of the defibrillating leads, or substitution of one lead system for another in order to facilitate arrhythmia conversion. In some cases, reliable arrhythmia conversion may not be obtained with any leads at the available AICD energy levels.Bipolar pacmakers may be used with the ENDOTAK Lead System and AICD pulse generator as long as the pacemaker and AICD pulse generator do not interact causing AICD pulse generator nondetection or false detection.The ENDOTAK SQ Patch Lead is intended for chronic subcutaneous or submuscular implantation in conjunction with an ENDOTAK C Lead. The ENDOTAK SQ Patch Leas is not intended for epicardial or pericardial placement.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Aug 26, 1993

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P910073
Regulatory pathway
Premarket approval application
Product code
LWS
Decision code
APPR
Decision date
Aug 26, 1993
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable cardioverter defibrillator (non-CRT).

Product code
LWS
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P910073 received

    Application receipt date recorded by FDA.

  2. P910073 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P910073. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P910073

Product / regulatory recordCompanyPathwayDecision dateSource
Boston ScientificPMA supplementSep 17, 2026FDA

Explore the linked device profile

Other records with product code LWS

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific

Headquarters
Not reported
FDA applicant address
4100 Hamline Ave. N, St Paul, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records